Organization
Department of Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy
6 abstracts
Abstract
Phase 3 THOR study: Results of erdafitinib (erda) versus chemotherapy (chemo) in patients (pts) with advanced or metastatic urothelial cancer (mUC) with select fibroblast growth factor receptor alterations (FGFRalt).Org: Department of Medical Oncology, National Cancer Center Hospital East, Chiba, Japan, Section of Radiotherapy and Imaging, Institute of Cancer Research and Royal Marsden NHS Foundation Trust, Sutton, United Kingdom, Medical Oncology Department, Institut de Cancérologie du Gard - CHU Caremeau, Nimes, France, Department of Medical Oncology, Centre Eugene Marquis, Rennes, France, Seoul National University Hospital, Seoul, Korea, Republic of (South),
Abstract
Activity of cabozantinib (CABO) plus durvalumab (DURVA) in patients (pts) with advanced urothelial carcinoma (UC) or non-UC variant histologies (VH) after platinum chemotherapy: Interim results from the phase 2 ARCADIA trial.Org: IRCCS Foundation National Cancer Institute, Milan, Italy, Department of Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy, IRCCS Ospedale San Raffaele, Milan, Italy, Medical Oncology Department, Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, Milan, Italy, Department of Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy,
Abstract
Sex differences in burden of adverse events in patients receiving immunotherapy.Org: Unit of Biostatistics for Clinical Research, Department of Epidemiology and Data Science, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy, Department of Oncology-Pathology, Karolinska Institutet, Theme Cancer. Oncology-Pathology department, Karolinska University Hospital-Solna, Solna, Sweden, National Institute for Cellular Biotechnology, School of Biotechnology, Dublin City University, Dublin, Ireland, Thoracic Oncology Unit, Medical Oncology Department, Fondazione IRCCS Istituto Nazionale Tumori, Milan, Italy, Head and Neck Cancer Medical Oncology 3 Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy,
Abstract
APPROACH trial: Multimodal approach in patients with mHSPC: A pragmatic, randomized, phase 3 trial of androgen-deprivation therapy (ADT) plus apalutamide (APA) versus ADT plus apalutamide (APA) and local treatment—Meet-URO 29 study.Org: Department of Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy, Department of Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy, Medical Oncology Department, Istituto Nazionale Tumori di Milano IRCCS, Milano, Italy, Medical Oncology Department, Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, Milan, Italy, Medical Oncology Department, Istituto Nazionale Tumori di Milano IRCCS, Milan, Italy,
Abstract
Negative selection of patients (pts) with HER2-positive and RAS wild-type (wt) metastatic colorectal cancer (mCRC) receiving dual HER2 blockade.Org: Department of Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy, Department of Gastroenterology and Gastrointestinal Oncology, National Cancer Center Hospital East, Kashiwa, Japan, Memorial Sloan Kettering Cancer Center, New York, NY, USA, Department of Oncology, Veneto Institute of Oncology IOV - IRCCS, Padua, Italy, Padua, Italy, Padua, Italy,
Abstract
Real-life use of cabozantinib as front-line therapy in metastatic renal cell carcinoma: The CabFRONT (Meet-URO 24) study.Org: Department of Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy, Department of Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy, Department of Health Sciences, University of Florence, Florence, Italy, Medical Oncology Unit 1, Department of Oncology, Istituto Oncologico Veneto IOV IRCCS, Padua, Italy, Oncology Unit, Foundation Casa Sollievo della Sofferenza IRCCS, San Giovanni Rotondo, Italy,